Akebia Therapeutics Inc (AKBA) concluded trading on Wednesday at a closing price of $1.70, with 7.72 million shares of worth about $13.13 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 28.79% during that period and on April 09, 2025 the price saw a gain of about 1.19%. Currently the company’s common shares owned by public are about 261.23M shares, out of which, 250.51M shares are available for trading.
Stock saw a price change of -11.92% in past 5 days and over the past one month there was a price change of -11.92%. Year-to-date (YTD), AKBA shares are showing a performance of -10.53% which increased to 11.11% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.80 but also hit the highest price of $2.89 during that period. The average intraday trading volume for Akebia Therapeutics Inc shares is 3.72 million. The stock is currently trading -15.46% below its 20-day simple moving average (SMA20), while that difference is down -15.17% for SMA50 and it goes to 1.08% higher than SMA200.
Akebia Therapeutics Inc (NASDAQ: AKBA) currently have 261.23M outstanding shares and institutions hold larger chunk of about 23.97% of that.
The stock has a current market capitalization of $444.09M and its 3Y-monthly beta is at 0.94. It has posted earnings per share of -$0.33 in the same period. It has Quick Ratio of 1.21. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for AKBA, volatility over the week remained 10.14% while standing at 10.06% over the month.
Stock’s fiscal year EPS is expected to rise by 43.18% while it is estimated to increase by 91.11% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Jefferies on April 01, 2025 offering a Buy rating for the stock and assigned a target price of $6 to it. Coverage by BTIG Research stated Akebia Therapeutics Inc (AKBA) stock as a Buy in their note to investors on November 29, 2023, suggesting a price target of $4 for the stock. On August 28, 2023, H.C. Wainwright Upgrade their recommendations, while on May 31, 2023, Piper Sandler Upgrade their ratings for the stock with a price target of $4. Stock get a Neutral rating from Piper Sandler on March 31, 2022.
